QUESTIONSPERSONALIZED MEDICINE In an Era of Health Care Reform
Venue: AAAS Headquarters
Location: Washington, Washington DC, United States
| Event Date/Time: Oct 26, 2009 | End Date/Time: Oct 27, 2009 |
Report as SpamDescription
In partnership with the Food and Drug Law Institute (FDLI), AAAS is convening a two-day colloquium on personalized medicine on October 26-27, 2009 at AAAS headquarters in Washington, DC. This event is the second in a series of three colloquia. The first colloquium was held on June 1-2, 2009 and can be viewed via webcast at http://www.aaas.org/spp/PM/Agenda.
The colloquium will address personalized medicine through a health care reform lens. Keynote speaker Francis Collins, NIH Director, will explain how his agency is addressing the scientific and policy challenges of personalized medicine, and a FDA official is invited to describe that agency’s role in personalized medicine. Other topics will include comparative effectiveness research; the use of health IT in research and clinical practice, as well as the ethical, legal, and policy implications of the transition to electronic health records; and the status of biomarker research, along with case studies illustrating the application of that research in targeting drug treatment, refining doses, and avoiding adverse events. At the colloquium’s conclusion, a panel will interact with the audience to discuss the difficult choices involved in clinical care in an era of personalized medicine from the perspective of a physician, a patient, an insurance official, and an attorney.
The colloquia series is free and open to the public, but registration is required.
WHAT: Colloquium II
Personalized Medicine
In an Era of Health Care Reform
WHEN: October 26-27, 2009
WHERE: AAAS Headquarters
1200 New York Ave., NW
Washington, DC
(12th and H Street entrance)
REGISTER: http://www.aaas.org/spp/PM/colloquia2
AAAS and FDLI would like to thank 3M, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celera, Greenwall Foundation, Hoffmann-La Roche, and Johnson & Johnson for their support.
The colloquium will address personalized medicine through a health care reform lens. Keynote speaker Francis Collins, NIH Director, will explain how his agency is addressing the scientific and policy challenges of personalized medicine, and a FDA official is invited to describe that agency’s role in personalized medicine. Other topics will include comparative effectiveness research; the use of health IT in research and clinical practice, as well as the ethical, legal, and policy implications of the transition to electronic health records; and the status of biomarker research, along with case studies illustrating the application of that research in targeting drug treatment, refining doses, and avoiding adverse events. At the colloquium’s conclusion, a panel will interact with the audience to discuss the difficult choices involved in clinical care in an era of personalized medicine from the perspective of a physician, a patient, an insurance official, and an attorney.
The colloquia series is free and open to the public, but registration is required.
WHAT: Colloquium II
Personalized Medicine
In an Era of Health Care Reform
WHEN: October 26-27, 2009
WHERE: AAAS Headquarters
1200 New York Ave., NW
Washington, DC
(12th and H Street entrance)
REGISTER: http://www.aaas.org/spp/PM/colloquia2
AAAS and FDLI would like to thank 3M, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celera, Greenwall Foundation, Hoffmann-La Roche, and Johnson & Johnson for their support.
Venue
1200 New York Ave., NW
MORE INFO ON THIS VENUE 